Title : Initial decline in eGFR to predict tolvaptan response in autosomal-dominant polycystic kidney disease.

Pub. Date : 2022 Jun

PMID : 35165806






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 BACKGROUND: Tolvaptan, a vasopressin V2 receptor antagonist, is used to treat autosomal-dominant polycystic kidney disease (ADPKD). Tolvaptan arginine vasopressin receptor 2 Homo sapiens